Autre sujet:
Les sigles BITAC, BQTT, GBFO et TLM sont souvent utilisés parmi le personnel SNCF mais ne sont repris dans AUCUN règlement officiel.
Les sigles BITAC, BQTT, GBFO et TLM sont souvent utilisés parmi le personnel SNCF mais ne sont repris dans AUCUN règlement officiel.
November 20, 2024 at 4:03 PM
Autre sujet:
Les sigles BITAC, BQTT, GBFO et TLM sont souvent utilisés parmi le personnel SNCF mais ne sont repris dans AUCUN règlement officiel.
Les sigles BITAC, BQTT, GBFO et TLM sont souvent utilisés parmi le personnel SNCF mais ne sont repris dans AUCUN règlement officiel.
Addiopizzo Travel è entrata nella cinquina dei finalisti del Premio Bitac (Borsa Italiana del Turismo Cooperativo e Associativo).
Soddisfazioni.
Soddisfazioni.
February 18, 2025 at 1:13 PM
Addiopizzo Travel è entrata nella cinquina dei finalisti del Premio Bitac (Borsa Italiana del Turismo Cooperativo e Associativo).
Soddisfazioni.
Soddisfazioni.
get the work done bitac
September 28, 2026 at 10:41 PM
get the work done bitac
thyssenkrupp nucera secures another chlor-alkali win in China — Hongniu Lanzhou's first-ever entry into the sector, built on nucera's e-BiTAC v7 technology in Northwest China.
Steady orders in a volatile market. Full story:
fcw.sh/04OOoW
#Electrolysis #ChlorAlkali #ChinaEnergy
Steady orders in a volatile market. Full story:
fcw.sh/04OOoW
#Electrolysis #ChlorAlkali #ChinaEnergy
September 29, 2026 at 3:24 PM
thyssenkrupp nucera secures another chlor-alkali win in China — Hongniu Lanzhou's first-ever entry into the sector, built on nucera's e-BiTAC v7 technology in Northwest China.
Steady orders in a volatile market. Full story:
fcw.sh/04OOoW
#Electrolysis #ChlorAlkali #ChinaEnergy
Steady orders in a volatile market. Full story:
fcw.sh/04OOoW
#Electrolysis #ChlorAlkali #ChinaEnergy
Permets moi de reprendre le sigle BITAC pour former nos étudiants aux opérations en centre de contrôle nanosatellite 🙏
November 20, 2024 at 7:42 PM
Permets moi de reprendre le sigle BITAC pour former nos étudiants aux opérations en centre de contrôle nanosatellite 🙏
🎉 #VERAXA Biotech begins trading today on NASDAQ (#$VRXA)!
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
June 11, 2026 at 1:30 PM
🎉 #VERAXA Biotech begins trading today on NASDAQ (#$VRXA)!
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
POLAND: AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline
rcnworldwidemedia.blogspot.com/2026/07/pola...
rcnworldwidemedia.blogspot.com/2026/07/pola...
POLAND: AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline
rcnworldwidemedia.blogspot.com
July 14, 2026 at 4:45 PM
POLAND: AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline
rcnworldwidemedia.blogspot.com/2026/07/pola...
rcnworldwidemedia.blogspot.com/2026/07/pola...
🧬 #$VRXA looks ahead: doubling down on its BiTAC® platform, with VXA-102 targeted IND/CTA-ready by early 2028. Plans to monetize non-BiTAC assets to fuel growth, plus VXA-901 (AML) & HER2-ADC open for partnering.
Read more: bit.ly/4eZPKU6
#Biotech #Oncology
Read more: bit.ly/4eZPKU6
#Biotech #Oncology
July 6, 2026 at 2:32 PM
🧬 #$VRXA looks ahead: doubling down on its BiTAC® platform, with VXA-102 targeted IND/CTA-ready by early 2028. Plans to monetize non-BiTAC assets to fuel growth, plus VXA-901 (AML) & HER2-ADC open for partnering.
Read more: bit.ly/4eZPKU6
#Biotech #Oncology
Read more: bit.ly/4eZPKU6
#Biotech #Oncology
Lontani dal #turismo di massa e vicini alle #persone: la #Bitac 2025 ad #Assisi
La Borsa italiana del turismo cooperativo e associativo si terrà in #Umbria il 20 e il 21 febbraio organizzata dall'Alleanza delle #cooperative
www.metropoli.online/lontani-dal-...
La Borsa italiana del turismo cooperativo e associativo si terrà in #Umbria il 20 e il 21 febbraio organizzata dall'Alleanza delle #cooperative
www.metropoli.online/lontani-dal-...
Lontani dal turismo di massa e vicini alle persone: la Bitac 2025 ad Assisi - metropoli.online
La Borsa italiana del turismo cooperativo e associativo si terrà in Umbria il 20 e il 21 febbraio organizzata dall'Alleanza delle cooperative
www.metropoli.online
February 18, 2025 at 6:16 PM
Lontani dal #turismo di massa e vicini alle #persone: la #Bitac 2025 ad #Assisi
La Borsa italiana del turismo cooperativo e associativo si terrà in #Umbria il 20 e il 21 febbraio organizzata dall'Alleanza delle #cooperative
www.metropoli.online/lontani-dal-...
La Borsa italiana del turismo cooperativo e associativo si terrà in #Umbria il 20 e il 21 febbraio organizzata dall'Alleanza delle #cooperative
www.metropoli.online/lontani-dal-...
VERAXA Biotech (NASDAQ: VRXA) partners with Ardigen to bring AI-driven tools to its BiTAC cancer drug platform, aiming to improve tumor targeting and reduce toxicity by analyzing large clinical datasets. A key step forward in precision oncology. #Oncology #Biotech
July 13, 2026 at 5:04 PM
VERAXA Biotech (NASDAQ: VRXA) partners with Ardigen to bring AI-driven tools to its BiTAC cancer drug platform, aiming to improve tumor targeting and reduce toxicity by analyzing large clinical datasets. A key step forward in precision oncology. #Oncology #Biotech
🤝 Join #VERAXA Biotech at BIO International, San Diego, June 22-25!
Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.
Schedule via BIO One-on-One!
Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.
Schedule via BIO One-on-One!
June 15, 2026 at 1:03 PM
🤝 Join #VERAXA Biotech at BIO International, San Diego, June 22-25!
Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.
Schedule via BIO One-on-One!
Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.
Schedule via BIO One-on-One!
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as CSO to advance its proprietary BiTAC T cell engager platform toward clinical development. Preclinical data at AACR showed promising selective cancer cell activity. #Oncology #Biotech
September 10, 2026 at 8:00 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as CSO to advance its proprietary BiTAC T cell engager platform toward clinical development. Preclinical data at AACR showed promising selective cancer cell activity. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance expertise to accelerate its next-gen cancer therapy pipeline and proprietary BiTAC platform. #Biotech #Oncology
September 8, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance expertise to accelerate its next-gen cancer therapy pipeline and proprietary BiTAC platform. #Biotech #Oncology
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance experience to support its capital strategy and BiTAC cancer therapy platform. #Biotech #Oncology
September 4, 2026 at 8:03 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance experience to support its capital strategy and BiTAC cancer therapy platform. #Biotech #Oncology
We’re delighted to welcome Raju Willener, MBA, MA, as our new Chief Financial Officer! His strategic expertise will help advance our BiTAC® platform and shift our pipeline toward the clinic.
For more see: bit.ly/3Tb45pK
#$VRXA #Biotech #ADCs #TCEs
For more see: bit.ly/3Tb45pK
#$VRXA #Biotech #ADCs #TCEs
September 4, 2026 at 12:30 PM
We’re delighted to welcome Raju Willener, MBA, MA, as our new Chief Financial Officer! His strategic expertise will help advance our BiTAC® platform and shift our pipeline toward the clinic.
For more see: bit.ly/3Tb45pK
#$VRXA #Biotech #ADCs #TCEs
For more see: bit.ly/3Tb45pK
#$VRXA #Biotech #ADCs #TCEs
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 cancer program beyond discovery, filing first patents on its BiTAC platforms while building a diversified oncology pipeline of bispecific antibodies and ADCs. #Oncology #Biotech
August 27, 2026 at 11:13 AM
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 cancer program beyond discovery, filing first patents on its BiTAC platforms while building a diversified oncology pipeline of bispecific antibodies and ADCs. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) receives favorable regulatory guidance from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially clearing the path toward clinical trials. Preclinical data showed selective dual-biomarker cancer cell targeting. #Oncology #Biotech
August 27, 2026 at 11:13 AM
VERAXA Biotech (NASDAQ: VRXA) receives favorable regulatory guidance from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially clearing the path toward clinical trials. Preclinical data showed selective dual-biomarker cancer cell targeting. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) advances its dual-targeting BiTAC cancer platform, with its lead T-cell engager nearing IND-enabling studies and VXA-222 bispecific ADC moving past discovery. 50+ patents support a growing oncology pipeline. #Oncology #Biotech
August 27, 2026 at 11:18 AM
VERAXA Biotech (NASDAQ: VRXA) advances its dual-targeting BiTAC cancer platform, with its lead T-cell engager nearing IND-enabling studies and VXA-222 bispecific ADC moving past discovery. 50+ patents support a growing oncology pipeline. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) is advancing its BiTAC platform in antibody-drug conjugates and T-cell engagers, two areas drawing massive pharma investment. Its pipeline targets future partnerships, licensing deals, and asset transactions. #Biotech #AntibodyTherapeutics
August 7, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) is advancing its BiTAC platform in antibody-drug conjugates and T-cell engagers, two areas drawing massive pharma investment. Its pipeline targets future partnerships, licensing deals, and asset transactions. #Biotech #AntibodyTherapeutics
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as Chief Scientific Officer to lead its BiTAC cancer therapy platform toward clinical development. Recent regulatory clarity from Germany's Paul-Ehrlich-Institute adds momentum to its lead oncology program. #Biotech #Oncology
July 30, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as Chief Scientific Officer to lead its BiTAC cancer therapy platform toward clinical development. Recent regulatory clarity from Germany's Paul-Ehrlich-Institute adds momentum to its lead oncology program. #Biotech #Oncology
VERAXA Biotech (NASDAQ: VRXA) now holds 50+ patents across 14 countries protecting its next-gen BiTAC cancer therapy platforms, with core technology protection expected through at least 2047. #Oncology #Biotech
July 29, 2026 at 11:01 PM
VERAXA Biotech (NASDAQ: VRXA) now holds 50+ patents across 14 countries protecting its next-gen BiTAC cancer therapy platforms, with core technology protection expected through at least 2047. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as Chief Scientific Officer to lead its BiTAC cancer therapy platform toward clinical development. Recent regulatory clarity from Germany's Paul-Ehrlich-Institute adds momentum to the pipeline. #Biotech #Oncology
July 29, 2026 at 11:02 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as Chief Scientific Officer to lead its BiTAC cancer therapy platform toward clinical development. Recent regulatory clarity from Germany's Paul-Ehrlich-Institute adds momentum to the pipeline. #Biotech #Oncology